CU20170099A7 - Terapias de combinación para el tratamiento de cánceres - Google Patents

Terapias de combinación para el tratamiento de cánceres

Info

Publication number
CU20170099A7
CU20170099A7 CUP2017000099A CU20170099A CU20170099A7 CU 20170099 A7 CU20170099 A7 CU 20170099A7 CU P2017000099 A CUP2017000099 A CU P2017000099A CU 20170099 A CU20170099 A CU 20170099A CU 20170099 A7 CU20170099 A7 CU 20170099A7
Authority
CU
Cuba
Prior art keywords
cancer treatment
combination therapies
methods
entospletinib
navitoclax
Prior art date
Application number
CUP2017000099A
Other languages
English (en)
Inventor
Paolo Julie A Di
Randall Mark Jones
Daniel B Tumas
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55398445&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20170099(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of CU20170099A7 publication Critical patent/CU20170099A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

<p>Se proporcionan en el presente documento métodos que se relacionan con la estrategia<br /> terapéutica para el tratamiento del cáncer, incluyendo malignidades hematológicas. En particular, los<br /> métodos incluyen la administración de entospletinib y un inhibidor de Bcl-2, tal como venetoclax,<br /> navitoclax y ABT-737.<br />  </p>
CUP2017000099A 2015-02-03 2016-01-29 Terapias de combinación para el tratamiento de cánceres CU20170099A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562111604P 2015-02-03 2015-02-03
PCT/US2016/015727 WO2016126552A1 (en) 2015-02-03 2016-01-29 Combination therapies for treating cancers

Publications (1)

Publication Number Publication Date
CU20170099A7 true CU20170099A7 (es) 2018-03-13

Family

ID=55398445

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2017000099A CU20170099A7 (es) 2015-02-03 2016-01-29 Terapias de combinación para el tratamiento de cánceres

Country Status (25)

Country Link
US (2) US20180117052A1 (es)
EP (1) EP3253385A1 (es)
JP (1) JP2018503653A (es)
KR (1) KR20170104616A (es)
CN (1) CN107205992A (es)
AU (1) AU2016215643A1 (es)
BR (1) BR112017016019A2 (es)
CA (1) CA2974828A1 (es)
CL (1) CL2017001943A1 (es)
CO (1) CO2017007662A2 (es)
CR (1) CR20170352A (es)
CU (1) CU20170099A7 (es)
EA (1) EA201791516A1 (es)
EC (1) ECSP17048849A (es)
GT (1) GT201700167A (es)
IL (1) IL253573A0 (es)
MA (1) MA41449A (es)
MD (1) MD20170073A2 (es)
MX (1) MX2017009724A (es)
PE (1) PE20171241A1 (es)
PH (1) PH12017550063A1 (es)
SG (1) SG11201706107SA (es)
SV (1) SV2017005489A (es)
TW (1) TW201639573A (es)
WO (1) WO2016126552A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102307581B (zh) 2008-12-08 2016-08-17 吉利德康涅狄格股份有限公司 咪唑并哌嗪syk抑制剂
US9562056B2 (en) 2010-03-11 2017-02-07 Gilead Connecticut, Inc. Imidazopyridines Syk inhibitors
US20160168155A1 (en) * 2013-07-30 2016-06-16 Gilead Connecticut, Inc. Polymorph of syk inhibitors
AU2014296184B2 (en) 2013-07-31 2017-04-27 Gilead Sciences, Inc. Syk inhibitors
WO2015084992A1 (en) 2013-12-04 2015-06-11 Gilead Sciences, Inc. Methods for treating cancers
UY35898A (es) 2013-12-23 2015-07-31 Gilead Sciences Inc ?compuestos inhibidores de syk y composiciones que los comprenden?.
JP6310144B2 (ja) 2014-07-14 2018-04-18 ギリアード サイエンシーズ， インコーポレイテッド がんを処置するための組み合わせ
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
US10759798B2 (en) * 2016-09-14 2020-09-01 Hangzhou Solipharma Co., Ltd. ABT-199 addition salt and crystal form thereof, preparation method thereof, and pharmaceutical composition thereof
EP3512519A1 (en) 2016-09-14 2019-07-24 Gilead Sciences, Inc. Syk inhibitors
WO2018200841A1 (en) * 2017-04-28 2018-11-01 Actinium Pharmaceuticals, Inc. Method for treating cancer using a bcl-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic
CN115028640A (zh) 2017-08-25 2022-09-09 吉利德科学公司 Syk抑制剂的多晶型物
JP2021510165A (ja) 2018-01-10 2021-04-15 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー ベンズアミド化合物
JP2022521413A (ja) 2019-02-22 2022-04-07 クロノス バイオ インコーポレイテッド Ｓｙｋ阻害剤としての縮合ピラジンの固体形態
SG11202113356XA (en) 2019-06-12 2021-12-30 Juno Therapeutics Inc Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein
EP4069233A4 (en) * 2019-12-04 2024-03-13 Ascentage Pharma Suzhou Co Ltd PHARMACEUTICAL COMBINATION AND USE THEREOF
WO2022133030A1 (en) 2020-12-16 2022-06-23 Juno Therapeutics, Inc. Combination therapy of a cell therapy and a bcl2 inhibitor
AU2022255990A1 (en) * 2021-04-05 2023-10-26 Pinotbio, Inc. Combined therapy of 4'-thio-5-aza-2'-deoxycytidine and venetoclax
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965288A (en) 1988-02-25 1990-10-23 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5059714A (en) 1988-02-25 1991-10-22 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5021456A (en) 1988-02-25 1991-06-04 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5252608A (en) 1988-02-25 1993-10-12 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4943593A (en) 1988-02-25 1990-07-24 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5182297A (en) 1988-02-25 1993-01-26 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5120764A (en) 1988-11-01 1992-06-09 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4997854A (en) 1989-08-25 1991-03-05 Trustees Of Boston University Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates
FR2828206B1 (fr) 2001-08-03 2004-09-24 Centre Nat Rech Scient Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
US7932260B2 (en) 2004-05-13 2011-04-26 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
US20090142345A1 (en) 2005-03-15 2009-06-04 Takeda Pharmaceutical Company Limited Prophylactic/therapeutic agent for cancer
PT1888550E (pt) 2005-05-12 2014-09-03 Abbvie Bahamas Ltd Promotores de apoptose
EP2537529B1 (en) 2007-08-02 2018-10-17 Gilead Biologics, Inc. Loxl2 inhibitory antibodies and uses thereof
US8652843B2 (en) 2008-08-12 2014-02-18 Oncomed Pharmaceuticals, Inc. DDR1-binding agents and methods of use thereof
TWI478922B (zh) * 2008-12-08 2015-04-01 Gilead Connenticut Inc 作為脾臟酪胺酸激酶（Ｓｙｋ）抑制劑之咪唑並吡化合物
US8450321B2 (en) * 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
US8362013B2 (en) 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI598347B (zh) 2009-07-13 2017-09-11 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
CN102695702A (zh) 2009-09-20 2012-09-26 雅培制药有限公司 用于治疗bcl-2蛋白相关疾病的abt-263晶体形式和溶剂化物
CN103370080A (zh) 2010-02-04 2013-10-23 吉联亚生物科技有限公司 结合赖氨酰氧化酶样2（loxl2）的抗体和其使用方法
WO2011133668A2 (en) * 2010-04-20 2011-10-27 President And Fellows Of Harvard College Methods and compositions for the treatment of cancer
PE20131376A1 (es) 2010-08-27 2013-11-25 Gilead Biologics Inc Anticuerpos para metaloproteinasa-9 de matriz
US8722657B2 (en) 2010-11-23 2014-05-13 Abbvie Inc. Salts and crystalline forms of an apoptosis-inducing agent
WO2013027802A1 (ja) 2011-08-23 2013-02-28 中外製薬株式会社 抗腫瘍活性を有する新規な抗ｄｄｒ１抗体
GB201115529D0 (en) 2011-09-08 2011-10-26 Imp Innovations Ltd Antibodies, uses and methods
CN104024257A (zh) 2011-10-04 2014-09-03 吉利德卡利斯托加有限责任公司 Pi3k的新的喹喔啉抑制剂
UY34573A (es) 2012-01-27 2013-06-28 Gilead Sciences Inc Inhibidor de la quinasa que regula la señal de la apoptosis
WO2013116562A1 (en) 2012-02-03 2013-08-08 Gilead Calistoga Llc Compositions and methods of treating a disease with (s)-4 amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
CA2882134A1 (en) * 2012-08-14 2014-02-20 Gilead Calistoga Llc Combination therapies for treating cancer
JP6408993B2 (ja) * 2012-09-07 2018-10-17 ジェネンテック， インコーポレイテッド タイプＩＩ抗ＣＤ２０抗体と選択的Ｂｃｌ−２インヒビターの併用療法
AR092662A1 (es) 2012-09-24 2015-04-29 Gilead Sciences Inc Anticuerpos anti-ddr1
JP6207100B2 (ja) 2012-12-21 2017-10-04 ギリアード カリストガ エルエルシー イソキノリノンまたはキナゾリノンホスファチジルイノシトール３−キナーゼ阻害剤
CA2895782C (en) 2012-12-21 2017-08-22 Gilead Calistoga Llc Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors
NZ714710A (en) 2013-06-14 2016-11-25 Gilead Sciences Inc Phosphatidylinositol 3-kinase inhibitors
MD4684B1 (ro) 2013-07-30 2020-03-31 Gilead Connecticut INc. Formulări pe bază de imidazopirazine în calitate de inhibitori SYK
US20160168155A1 (en) 2013-07-30 2016-06-16 Gilead Connecticut, Inc. Polymorph of syk inhibitors
EP2886146A1 (en) * 2013-12-20 2015-06-24 Sanofi-Aventis Deutschland GmbH Needle safety device and drug delivery device

Also Published As

Publication number Publication date
PH12017550063A1 (en) 2018-02-05
EP3253385A1 (en) 2017-12-13
ECSP17048849A (es) 2017-10-31
CR20170352A (es) 2017-09-29
US20160220573A1 (en) 2016-08-04
PE20171241A1 (es) 2017-08-24
US20180117052A1 (en) 2018-05-03
WO2016126552A1 (en) 2016-08-11
EA201791516A1 (ru) 2018-01-31
SG11201706107SA (en) 2017-08-30
AU2016215643A1 (en) 2017-08-10
TW201639573A (zh) 2016-11-16
CL2017001943A1 (es) 2018-03-02
CN107205992A (zh) 2017-09-26
JP2018503653A (ja) 2018-02-08
MX2017009724A (es) 2017-11-17
SV2017005489A (es) 2017-10-17
BR112017016019A2 (pt) 2018-03-20
IL253573A0 (en) 2017-09-28
CA2974828A1 (en) 2016-08-11
CO2017007662A2 (es) 2017-10-20
KR20170104616A (ko) 2017-09-15
GT201700167A (es) 2017-11-02
MD20170073A2 (ro) 2018-02-28
MA41449A (fr) 2017-12-12

Similar Documents

Publication Publication Date Title
CU20170099A7 (es) Terapias de combinación para el tratamiento de cánceres
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
NI201900019A (es) Inhibidores de procesos metabólicos celulares
CL2018001134A1 (es) Composiciones y métodos para inhibir la actividad arginasa
UY36307A (es) Terapias combinadas para el tratamiento del cáncer
CL2017002786A1 (es) Referencia cruzada a solicitudes relacionadas
CL2017002996A1 (es) Compuestos alqueno tetrasustituidos y su uso
CR20150316A (es) Compuestos y sus métodos de empleo
AR102553A1 (es) Terapia de combinación con agonistas de unión ox40 e inhibidores de tigit
ECSP17013903A (es) Protein kinase c inhibitors and methods of their use
GT201500248A (es) Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes
CL2015000699A1 (es) Métodos para tratamiento de cáncer.
NI201500094A (es) Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y métodos de tratamiento con los mismos.
ES2765949T8 (es) Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer
NI201400111A (es) Tratamiento del cáncer con inhibidores tor cinasa
CL2015000744A1 (es) Combinación de regorafenib y ácido acetilsalicílico para el tratamiento del cáncer.
UY36075A (es) Derivados de tubulisina
CR20180228A (es) Terapia adjunta con 25-hidroxi vitamina d y articulos de la misma
CL2015002571A1 (es) Composiciones y métodos para le diagnostico y tratamiento del cáncer hepático.
NI201400112A (es) Tratamiento del cáncer con inhibidores tor cinasa
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
CO2019000753A2 (es) Métodos para tratar el cáncer de próstata
NI201500063A (es) Tratamiento de cáncer con pomalidomida en un individuo con daño renal
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
DOP2015000298A (es) Compuestos nuevos para el tratamiento del cáncer